Phase 2 N=16 Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma
Relapsed Ewing Sarcoma · Refractory Ewing Sarcoma
Primary: Number of Participants With a Metabolic Response as Evaluated by PERCIST v1.0 — 1; 2; 4; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=17 Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy
Ewing's Sarcoma · Primitive Neuroectodermal Tumor (PNET) · Askin's Tumor of the Chest Wall
Primary: Overall Response Rate (ORR) — 0 Participants
N/A N=35 Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors
Ewing Sarcoma of Bone · Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Primary: Incidence of Death — 0 participants
Phase 3 N=642 Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
Localized Extraskeletal Ewing Sarcoma · Peripheral Primitive Neuroectodermal Tumor of Bone · Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
Primary: Event-Free Survival — 77.64; 78.79 Percent Probability
Phase 2 N=12 Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma
Ewing's Sarcoma
Primary: Objective Response Rate of Olaparib — 0 Participants
Phase 2 N=29 Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma
Liposarcoma,Myxoid
Primary: Percentage of Participants With Pathological Complete Response (pCR) — 13 percentage of participants
Phase 2 N=50 Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors
Previously Treated Childhood Rhabdomyosarcoma · Recurrent Childhood Rhabdomyosarcoma · Recurrent Childhood Soft Tissue Sarcoma
Primary: Response (Complete Response [CR] and Partial Response [PR]) — 1; 0; 0; 0 participants
N/A N=545 Patterns of Care and Outcomes in Patients With Metastatic Bone Tumors (METABONE)
Metastatic Bone Tumor
Primary: Overall Survival (OS) — 21.5; 12.7; 26.6 months
Phase 2 N=44 Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma
Neuroblastoma · Sarcoma · Rhabdomyosarcoma-Embryonal
Primary: Number of Participants With a Positive Immune Response as Evidenced by the Delayed Type of Hypersensitivity (DTH) Reaction Assay — 0; 15 Participants — p=0.043
Phase 2 N=23 Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma
Neoplasms
Primary: Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator Assessment — 20; 40 Percentage of participants
Phase 2 N=10 Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors
Sarcoma
Primary: Overall Objective Response — 4; 1 participants
Phase 2 N=38 Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors
Sarcoma
Primary: Occurrence of Severe Toxicity — 1; 1 participants
Phase 2 N=7 Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma
Ewing Sarcoma of Bone · Extraosseous Ewing Sarcoma · Peripheral Primitive Neuroectodermal Tumor
Primary: The Occurrence of Limiting Toxicity in an Eligible and Evaluable Patient. — 0 number of toxicities
Phase 1 N=50 A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
Neoplasms
Primary: Objective Response Rate (ORR) — 50; 30.8; 20; 26.7 Percentage of Participants
N/A N=35 Hypofractionated Pre-operative Radiation Therapy for Soft Tissue Sarcomas of the Extremity and Chest-wall
Soft Tissue Sarcoma
Primary: Local Disease Control Assessed by Physical Examination — 0 Participants
Phase 2 N=10 Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors
Ewing's Sarcoma Family of Tumors
Primary: Objective Response Rate (ORR) — 14.2 percentage of participants
Phase 2 N=21 Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)
Relapsed/Refractory Rhabdomyosarcoma · Non-rhabdomyosarcoma Soft Tissue Sarcoma · Ewing Sarcoma
Primary: Percentage of Participants With Objective Response — 0; 0; 0 percentage of participants
Phase 2 N=52 Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial
Advanced and / or Metastatic Liposarcoma
Primary: Progression-free Survival (PFS) Assessed 12 Weeks After Start of Treatment — 54.1; 46.2 percentage of participants
Phase 2 N=25 Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma
Sarcoma
Primary: Number of Patients With Dose Limiting Toxicities. — 0; 1; 0 Participants
Phase 2 N=10 Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma
Sarcoma
Primary: Response — 10; 0 participants
Phase 1 N=65 Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors
Sarcoma, Ewing's
Primary: Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 3; 3; 3; 3 participants
Phase 2 N=98 Image-Guided Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Shoulder, Arm, Hip, or Leg
Lymphedema · Musculoskeletal Complications · Radiation Fibrosis
Primary: Rate of Late Radiation Morbidity (≥ Grade 2 Lymphedema, Subcutaneous Fibrosis, or Joint Stiffness) at 2 Years From the Start of Radiotherapy as Measured by EORTC/RTOG…
N/A N=48 Assessment of Helical Tomotherapy Radiotherapy (54 Gy) Followed by Surgery in Retro-peritoneal Liposarcoma
Liposarcoma
Primary: Cumulative Incidence Rate of Local Recurrence and Competing Risks (All Patients) — 16.89; 10.42 percentage of participants
N/A N=14 Stereotactic Radiation Therapy for Pediatric Sarcomas
Sarcoma · Metastatic Disease · Bony Sites
Primary: Lesion-specific Local Control at 6 Months Post-SBRT as Assessed by Percentage of Lesions Locally Controlled — 95 percentage of lesions
Phase 2 N=17 External Beam Radiation With Intratumoral Injection of Dendritic Cells As Neo-Adjuvant Treatment for Sarcoma
Soft Tissue Sarcoma
Primary: Overall Response Rate (ORR) — 9; 3; 6 participants
N/A N=2,165 Patterns of Care and Outcomes in METAstatic Soft Tissue SARComa
Sarcoma · Metastases · Chemotherapy
Primary: Correlation Between Time to Next Treatment (TNT) and Overall Survival (OS) Under First-line Treatment — 0.76 correlation coefficient
N/A N=9 (SBRT) and (ART) for Pulmonary Metastases From Soft Tissue Sarcomas
Stage IV Adult Soft Tissue Sarcoma · Sarcoma,Soft Tissue
Primary: Number of Adverse Events of Grade ≥ 3 by CTCAE Criteria. — 8 events
Phase 2 N=60 Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas
Sarcoma
Primary: Number of Participants With Engraftment — 23 Participants
N/A N=7 A Phase II Trial of Preoperative Proton Therapy in Soft-tissue Sarcomas of the Extremities and Body Wall
Soft Tissue Sarcoma
Primary: Late Radiation Toxicities at 2 Years From the Start of Radiation Treatment — 0 Participants
N/A N=266 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma
Sarcoma
Primary: Number of Patients With Abdominal Recurrence or Death — 72; 73; 61; 60 Participants — p=0.955